Natural products with antiplatelet action

Current Pharmaceutical Design

Volumn 23, Issue 8, 2017, Pages 1228-1246

  Hirsch, Gabriela Elisa ^a,b   Viecili, Paulo Ricardo Nazário ^a,b   de Almeida, Amanda Spring ^a,b   Nascimento, Sabrina ^a,b   Porto, Fernando Garcez ^a,b   Otero, Juliana ^a,b   Schmidt, Aline ^a,b   Da Silva, Brenda ^a,b   Parisi, Mariana Migliorini ^a,b   Klafke, Jonatas Zeni ^a,b  

^a UNIVERSIDADE DE CRUZ ALTA   (Brazil)

^b Centro de Ensino e Pesquisa   (Brazil)

Author keywords

Agonists; Antiaggregatory activity; Cardiovascular diseases; Medicinal plants; Phytochemicals; Platelet aggregation

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; CAMPOMANESIA XANTHOCARPA EXTRACT; COUMARIN DERIVATIVE; CURCUMIN; FLAVONOID; FREE RADICAL; GARLIC EXTRACT; GINGER EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HYPERICUM PERFORATUM EXTRACT; NATURAL PRODUCT; NITRIC OXIDE; ONION EXTRACT; PLANT EXTRACT; POLYPHENOL; SAPONIN DERIVATIVE; SEROTONIN; TERPENOID; TERPENOID DERIVATIVE; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT;

ALTERNATIVE MEDICINE; ANTICOAGULATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CURCUMA LONGA; GARLIC; GEOGRAPHIC DISTRIBUTION; GINGER; GINKGO BILOBA; GINSENG; GUAVIROVA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERICUM PERFORATUM; INFLAMMATORY DISEASE; MEDICINAL PLANT; NONHUMAN; ONION; PHYTOCHEMISTRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN ALLERGY; TEA; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; CHEMISTRY; DRUG EFFECTS; ISOLATION AND PURIFICATION; METABOLISM; THROMBOCYTE;

BIOLOGICAL PRODUCTS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; HUMANS; PLANTS, MEDICINAL; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 85020929801     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612823666161123151611     Document Type: Review

References (224)

1. Xiang YZ, Kang LY, Gao XM, Shang HC, Zhang JH, Zhang BL. Strategies for antiplatelet targets and agents. Thrombosis Res 2008; 123(1): 35-49.
2. Davi G, Patrono C. Mechanisms of disease: Platelet activation and atherothrombosis. New Engl J Med 2007; 357(24): 2482-94.
3. Riccioni G, Sblendorio V. Atherosclerosis: from biology to pharmacological treatment. J Geriatr Cardiol 2012; 9(3): 305-17.
4. Chen C, Yang FQ, Zhang Q, Wang FQ, Hu YJ, Xia ZN. Natural products for antithrombosis. Evid-Based Compl Alt 2015.
5. Moro MA, Russel RJ, Cellek S, et al. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci USA 1996; 93(4): 1480-5.
6. Radomski MW, Vallance P, Whitley G, Foxwell N, Moncada S. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res 1993; 27(7): 1380-2.
7. Weksler BB, Marcus AJ, Jaffe EA. Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci USA 1977; 74(9): 3922-6.
8. Furie B, Furie BC. Mechanisms of disease: Mechanisms of thrombus formation. New Engl J Med 2008; 359(9): 938-49.
9. Chen D, Bernstein AM, Lemons PP, Whiteheart SW. Molecular mechanisms of platelet exocytosis: role of SNAP-23 and syntaxin 2 in dense core granule release. Blood 2000; 95(3): 921-9.
10. Flaumenhaft R. Molecular basis of platelet granule secretion. Arteriosclerosis, Thrombosis, Vascular Biol 2003; 23(7): 1152-60.
11. Rendu F, Brohard-Bohn B. The platelet release reaction: granules’ constituents, secretion and functions. Platelets 2001; 12(5): 261-73.
12. Bergmeier W, Stefanini L. Novel molecules in calcium signaling in platelets. J thrombosis and haemostasis: JTH 2009; 7 Suppl 1: 187-90.
13. Thijs T, Nuyttens BP, Deckmyn H, Broos K. Platelet physiology and antiplatelet agents. Clin Chem Lab Med 2010; 48 Suppl 1: S3-13.
14. Jagroop IA, Kakafika AI, Mikhailidis DP. Platelets and vascular risk: An option for treatment. Curr Pharm Des 2007; 13(16): 1669-83.
15. Tsuchiya H. Membrane interactions of phytochemicals as their molecular mechanism applicable to the discovery of drug leads from plants. Molecules 2015; 20(10): 18923-66.
16. Morgan LT, Thomas CP, Kuhn H, O’Donnell VB. Thrombinactivated human platelets acutely generate oxidized docosahexaenoic-acid-containing phospholipids via 12-lipoxygenase. Biochem J 2010; 431(1): 141-8.
17. Kay-Mugford PA, Benn SJ, LaMarre J, Conlon PD. Cyclooxygenase expression in canine platelets and Madin-Darby canine kidney cells. Am J Veterinary Res 2000; 61(12): 1512-6.
18. Patrono C, Coller B, Fitzgerald GA, Hirsh J, Roth G. Plateletactive drugs: The relationships among dose, effectiveness, and side effects. Chest 2004; 126(3): 234s-64s.
19. Pratico D, Cyrus T, Li HW, FitzGerald GA. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 2000; 96(12): 3823-6.
20. Fang J, George MG, Gindi RM, et al. Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012). Am J Cardiol 2015; 115(7): 895-900.
21. Luepker RV, Steffen LM, Duval S, Zantek ND, Zhou X, Hirsch AT. Population Trends in Aspirin Use for Cardiovascular Disease Prevention 1980-2009: The Minnesota Heart Survey. J Am Heart Assoc 2015; 4(12).
22. Abou-Saleh H, Yacoub D, Theoret JF, et al. Endothelial progenitor cells bind and inhibit platelet function and thrombus formation. Circulation 2009; 120(22): 2230-9.
23. Armstrong RA. Platelet prostanoid receptors. Pharmacology & therapeutics 1996; 72(3): 171-91.
24. Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. Seminars in thrombosis and hemostasis 2003; 29(5): 435-50.
25. Chu LY, Liou JY, Wu KK. Prostacyclin protects vascular integrity via PPAR/14-3-3 pathway. Prostaglandins Other Lipid Mediators 2015; 118-119: 19-27.
26. Liu B, Luo W, Zhang Y, Li H, Zhu N, Huang D, et al. Effect of celecoxib on cyclooxygenase-1-mediated prostacyclin synthesis and endothelium-dependent contraction in mouse arteries. Eur J Pharmacol 2013; 698(1-3): 354-61.
27. Halter F, Tarnawski AS, Schmassmann A, Peskar BM. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 2001; 49(3): 443-53.
28. Patrono C, Ciabattoni G, Pugliese F, et al. Inhibition of platelet cyclooxygenase by aspirin-like drugs: methods for in vitro and ex vivo assessment. Agents actions Supplements 1979(4): 138-46.
29. Sakata C, Kawasaki T, Kato Y, et al. ASP6537, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent antithrombotic effect without "aspirin dilemma". Thrombosis Res 2013; 132(1): 56-62.
30. Yeung J, Holinstat M. 12-lipoxygenase: a potential target for novel anti-platelet therapeutics. Cardiovascular Hematol Agents Med Chem 2011; 9(3): 154-64.
31. Gonzalez-Nunez D, Claria J, Rivera F, Poch E. Increased levels of 12(S)-HETE in patients with essential hypertension. Hypertension 2001; 37(2): 334-8.
32. Andre P, Delaney SM, LaRocca T, et al. P2Y(12) regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003; 112(3): 398-406.
33. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Seminars Thrombosis Hemostasis 2005; 31(2): 174-83.
34. Li N, Wallen NH, Ladjevardi M, Hjemdahl P. Effects of serotonin on platelet activation in whole blood. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis 1997; 8(8): 517-23.
35. Oliver KH, Duvernay MT, Hamm HE, Carneiro AM. Loss of Serotonin Transporter Function Alters ADP-Mediated Integrin alphaIIb/ beta3 Activation Through Dysregulation of the 5-HT2A Receptor. J Biol Chem 2016.
36. Shimizu M, Kanazawa K, Matsuda Y, et al. Serotonin-2A receptor gene polymorphisms are associated with serotonin-induced platelet aggregation. Thrombosis Res 2003; 112(3): 137-42.
37. Moncada S. Adventures in vascular biology: a tale of two mediators. Philos T R Soc B 2006; 361(1469): 735-59.
38. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357(Pt 3): 593-615.
39. Pearl RG, Rosenthal MH, Murad F, Ashton JP. Aminophylline potentiates sodium nitroprusside-induced hypotension in the dog. Anesthesiology 1984; 61(6): 712-5.
40. Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V, Ignarro LJ. Nitric oxide and atherosclerosis: an update. Nitric oxide: Biology and Chemistry/official J Nitric Oxide Society 2006; 15(4): 265-79.
41. Chen C, Yang FQ, Zhang Q, Wang FQ, Hu YJ, Xia ZN. Natural Products for Antithrombosis. Evidence-based complementary and alternative medicine: eCAM 2015; 2015: 876426.
42. Chua TK, Koh HL. Medicinal plants as potential sources of lead compounds with anti-platelet and anti-coagulant activities. Mini Rev Med Chem 2006; 6(6): 611-24.
43. Craig WJ. Health-promoting properties of common herbs. Am J Clin Nutr 1999; 70(3 Suppl): 491S-9S.
44. Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov 2015; 14(2): 111-29.
45. Sheridan C. Recasting natural product research. Nature biotechnology 2012; 30(5): 385-7.
46. Vickers A, Zollman C. ABC of complementary medicine. The manipulative therapies: osteopathy and chiropractic. Bmj 1999; 319(7218): 1176-9.
47. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environmental health perspectives 2001; 109 Suppl 1: 69-75.
48. Benzie IFF, Wachtel-Galor, S. Herbal medicine: An introduction to its history, usage, regulation, current trend and research needs. In: Benzie IFF, Wachtel-Galor, S., editor. HerbalMedicine: Biomolecular and Clinical Aspects. 2nd edition ed: CRC Press; 2011.
49. Bone K, Mills, S. Principles and practice of phytotherapy. 2nd edition ed: Elsevier Health Sciences; 2013.
50. Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta 2013; 1830(6): 3670-95.
51. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012; 75(3): 311-35.
52. Harvey AL. Medicines from nature: are natural products still relevant to drug discovery? Trends Pharmacol Sci 1999; 20(5): 196-8.
53. Heinrich M, Gibbons S. Ethnopharmacology in drug discovery: an analysis of its role and potential contribution. J pharmacy and Pharmacol 2001; 53(4): 425-32.
54. Valli M, dos Santos RN, Figueira LD, et al. Development of a natural products database from the biodiversity of Brazil. J Nat Prod 2013; 76(3): 439-44.
55. NCCIH: National Center for Complementary and Integrative Health. Complementary A, or Integrative Health: What’s In a Name? NCCIH: National Center for Complementary and Integrative Health. Complementary, Alternative, or Integrative Health: What’s In a Name? 2016. Available from: https://nccih.nih.gov/health/integrativehealth.
56. Chen XW, Sneed KB, Pan SY, et al. Herb-drug interactions and mechanistic and clinical considerations. Curr Drug Metabol 2012; 13(5): 640-51.
57. McEwen BJ. The influence of herbal medicine on platelet function and coagulation: a narrative review. Seminars Thrombosis Hemostasis 2015; 41(3): 300-14.
58. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John’s Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000; 294(1): 88-95.
59. Yue QY, Bergquist C, Gerden B. Safety of St John’s wort (Hypericum perforatum). Lancet 2000; 355(9203): 576-7.
60. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St John’s Wort: effect on CYP3A4 activity. Clinical pharmacology and therapeutics 2000; 67(5): 451-7.
61. Kim BH, Kim KP, Lim KS, et al. Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, twotreatment, two-sequence, single-dose crossover study in healthy Korean male volunteers. Clin Ther 2010; 32(2): 380-90.
62. Fuentes EP, I. Antiplatelet effects of natural bioactive compounds by multiple targets: food and drug interactions. J Functional Foods 2014; 6(1): 73-81.
63. Mousa SA. Antithrombotic effects of naturally derived products on coagulation and platelet function. Methods Mol Biol 2010; 663: 229-40.
64. Maheswaraiah A, Rao LJ, Naidu KA. Anti-platelet activity of water dispersible curcuminoids in rat platelets. Phytother Res 2015; 29(3): 450-8.
65. Prakash P, Misra A, Surin WR, et al. Anti-platelet effects of Curcuma oil in experimental models of myocardial ischemiareperfusion and thrombosis. Thrombosis Res 2011; 127(2): 111-8.
66. Xia Q, Wang X, Xu DJ, Chen XH, Chen FH. Inhibition of platelet aggregation by curdione from Curcuma wenyujin essential Oil. Thrombosis Res 2012; 130(3): 409-14.
67. Yan LG, Ruan JS, Zhang L, et al. Effect of aqueous extracts of several kinds of herbs on human platelet aggregation and expression of P-selectin in vitro. Chinese J Integrative Med 2015; 21(4): 286-90.
68. Kang WS, Lim IH, Yuk DY, et al. Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate. Thrombosis Res 1999; 96(3): 229-37.
69. Son DJ, Cho MR, Jin YR, et al. Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway. Prostaglandins, Leukotrienes, Essential Fatty Acids 2004; 71(1): 25-31.
70. Jin YR, Im JH, Park ES, et al. Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCgamma2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity. J Cardiovas Pharmacol 2008; 51(1): 45-54.
71. Cho HJ, Nam KS. Inhibitory effect of ginkgolide B on platelet aggregation in a cAMP-and cGMP-dependent manner by activated MMP-9. J Biochem Mol Biol 2007; 40(5): 678-83.
72. Cho HJ, Shon YH, Nam KS. Ginkgolide C inhibits platelet aggregation in cAMP-and cGMP-dependent manner by activating MMP-9. Biol Pharm Bull 2007; 30(12): 2340-4.
73. Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine 2005; 12(1-2): 10-6.
74. Ryu KH, Han HY, Lee SY, et al. Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time. Thrombosis Res 2009; 124(3): 328-34.
75. Srivastava KC. Effects of aqueous extracts of onion, garlic and ginger on platelet aggregation and metabolism of arachidonic acid in the blood vascular system: in vitro study 1984.
76. Nurtjahja-Tjendraputra E, Ammit AJ, Roufogalis BD, Tran VH, Duke CC. Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger. Thrombosis Res 2003; 111(4-5): 259-65.
77. Koo KL, Ammit AJ, Tran VH, Duke CC, Roufogalis BD. Gingerols and related analogues inhibit arachidonic acid-induced human platelet serotonin release and aggregation. Thrombosis Res 2001; 103(5): 387-97.
78. Srivastava KC. Effect of onion and ginger consumption on platelet thromboxane production in humans. Prostaglandins, Leukotrienes, Essential Fatty Acids 1989; 35(3): 183-5.
79. Endale M, Lee WM, Kamruzzaman SM, et al. Ginsenoside-Rp1 inhibits platelet activation and thrombus formation via impaired glycoprotein VI signalling pathway, tyrosine phosphorylation and MAPK activation. Br J Pharmacol 2012; 167(1): 109-27.
80. Jin YR, Yu JY, Lee JJ, et al. Antithrombotic and antiplatelet activities of Korean red ginseng extract. Basic Clin Pharmacol Toxicol 2007; 100(3): 170-5.
81. Lee IS, Kim SK, Jeon MH, Jeon WK. Ethyl acetate extract from tissue-cultured mountain ginseng adventitious roots inhibits in vitro platelet aggregation in whole human blood and augments peripheral blood flow in mice. J Ginseng Res 2011; 35(4): 442-8.
82. Bordia T, Mohammed N, Thomson M, Ali M. An evaluation of garlic and onion as antithrombotic agents. Prostaglandins Leukot Essent Fatty Acids 1996; 54(3): 183-6.
83. Ali M, Thomson M, Afzal M. Garlic and onions: their effect on eicosanoid metabolism and its clinical relevance. Prostaglandins, Leukotrienes, Essential Fatty Acids 2000; 62(2): 55-73.
84. Ro JY, Ryu JH, Park HJ, Cho HJ. Onion (Allium cepa L.) peel extract has anti-platelet effects in rat platelets. SpringerPlus 2015; 4: 17.
85. Suleria HA, Butt MS, Anjum FM, Saeed F, Khalid N. Onion: nature protection against physiological threats. Critic Rev Food Sci Nutr 2015; 55(1): 50-66.
86. Vilahur G, Badimon L. Antiplatelet properties of natural products. Vascular Pharmacol 2013; 59(3-4): 67-75.
87. Uebelhack R, Franke L. In vitro effects of St. John’s wort extract and hyperforin on 5 HT uptake and efflux in human blood platelets. Pharmacopsychiatry 2001; 34 Suppl 1: S146-7.
88. Albert D, Zundorf I, Dingermann T, Muller WE, Steinhilber D, Werz O. Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol 2002; 64(12): 1767-75.
89. Chung MI, Weng JR, Wang JP, Teng CM, Lin CN. Antiplatelet and anti-inflammatory constituents and new oxygenated xanthones from Hypericum geminiflorum. Planta Med 2002; 68(1): 25-9.
90. Lau WC, Welch TD, Shields T, Rubenfire M, Tantry US, Gurbel PA. The effect of St John’s Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovas Pharmacol 2011; 57(1): 86-93.
91. Gonzalez RE, Soto VC, Sance MM, Camargo AB, Galmarini CR. Variability of solids, organosulfur compounds, pungency and health-enhancing traits in garlic (Allium sativum L.) cultivars belonging to different ecophysiological groups. J Agric Food Chem 2009; 57(21): 10282-8.
92. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007; 595: 1-75.
93. Joe B, Vijaykumar M, Lokesh BR. Biological properties of curcumin-cellular and molecular mechanisms of action. Critic Rev Food Sci Nutr 2004; 44(2): 97-111.
94. Schieffer GW. Pressurized liquid extraction of curcuminoids and curcuminoid degradation products from turmeric (Curcuma longa) with subsequent HPLC assays. J Liquid Chromatography Related Technol 2002; 25: 3033-44.
95. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cellular and molecular life sciences: CMLS 2008; 65(11): 1631-52.
96. Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 2007; 595: 105-25.
97. Mak JC. Potential role of green tea catechins in various disease therapies: progress and promise. Clin Exp Pharmacol Physiol 2012; 39(3): 265-73.
98. Sato T, Miyata G. The nutraceutical benefit, part I: green tea. Nutrition 2000; 16(4): 315-7.
99. Balentine DA, Wiseman SA, Bouwens LC. The chemistry of tea flavonoids. Critic Rev Food Sci Nutr 1997; 37(8): 693-704.
100. Dufresne CJ, Farnworth ER. A review of latest research findings on the health promotion properties of tea. J Nutr Biochem 2001; 12(7): 404-21.
101. Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Critic Rev Food Sci Nutr 2003; 43(1): 89-143.
102. Mukhtar H, Ahmad N. Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr 2000; 71(6 Suppl): 1698S-702S; discussion 703S-4S.
103. Velayutham PB A, Liu, D. Green Tea Catechins and Cardiovascular Health: An Update. Curr Med Chem 2008; 15(18): 1840-50.
104. Sano M, Tabata M, Suzuki M, Degawa M, Miyase T, Maeda-Yamamoto M. Simultaneous determination of twelve tea catechins by high-performance liquid chromatography with electrochemical detection. Analyst 2001; 126(6): 816-20.
105. Thielecke F, Boschmann M. The potential role of green tea catechins in the prevention of the metabolic syndrome-a review. Phytochemistry 2009; 70(1): 11-24.
106. Yousaf S, Butt MS, Suleria HA, Iqbal MJ. The role of green tea extract and powder in mitigating metabolic syndromes with special reference to hyperglycemia and hypercholesterolemia. Food Function 2014; 5(3): 545-56.
107. Kang WS, Chung KH, Chung JH, Lee JY, Park JB, Zhang YH, et al. Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase. J Cardiovas Pharmacol 2001; 38(6): 875-84.
108. Christen YC, Y.; Droy-Lefaix, M.T. Effects of ginkgo biloba extract (EGb761) on aging and age-related disorders. Paris: Elsevier; 1995.
109. V. DFF. Ginkgo biloba Extract (EGb761): Pharmacological Activities and Clinical Applications. Paris: Elsevier; 1991.
110. T.A. VB. “Ginkgo biloba” 1ed ed: Harwood Academic Publishers; Amsterdan 2000.
111. Gardner CD, Zehnder JL, Rigby AJ, Nicholus JR, Farquhar JW. Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial. Blood Coagulation Fibrinolysis 2007; 18(8): 787-93.
112. Jiang X, Williams KM, Liauw WS, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2005; 59(4): 425-32.
113. Aruna D, Naidu MU. Pharmacodynamic interaction studies of Ginkgo biloba with cilostazol and clopidogrel in healthy human subjects. Br J Clin Pharmacol 2007; 63(3): 333-8.
114. Tuntiwechapikul W, Taka T, Songsomboon C, et al. Ginger extract inhibits human telomerase reverse transcriptase and c-Myc expression in A549 lung cancer cells. J Med Food 2010; 13(6): 1347-54.
115. Srivastava KC. Effects of aqueous extracts of onion, garlic and ginger on platelet aggregation and metabolism of arachidonic acid in the blood vascular system: in vitro study Prostaglandins Leukotrienes and Medicin 1984; 13(2): 227-35.
116. Lee CH, Kim JH. A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases. J Ginseng Res 2014; 38(3): 161-6.
117. Tesch BJ. Herbs commonly used by women: an evidence-based review. Disease-a-month: DM 2002; 48(10): 671-96.
118. Lau AJ, Toh DF, Chua TK, Pang YK, Woo SO, Koh HL. Antiplatelet and anticoagulant effects of Panax notoginseng: comparison of raw and steamed Panax notoginseng with Panax ginseng and Panax quinquefolium. J Ethnopharmacol 2009; 125(3): 380-6.
119. Hubbard GP, Wolffram S, de Vos R, Bovy A, Gibbins JM, Lovegrove JA. Ingestion of onion soup high in quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in man: a pilot study. Br J Nutr 2006; 96(3): 482-8.
120. Cavagnaro PF, Galmarini CR. Effect of processing and cooking conditions on onion (Allium cepa L.) induced antiplatelet activity and thiosulfinate content. J Agric Food Chem 2012; 60(35): 8731-7.
121. Steiner M, Lin RS. Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract. J Cardiovas Pharmacol 1998; 31(6): 904-8.
122. Bordia A, Verma SK, Srivastava KC. Effect of garlic on platelet aggregation in humans: a study in healthy subjects and patients with coronary artery disease. Prostaglandins, Leukotrienes, Essential Fatty Acids 1996; 55(3): 201-5.
123. Lorenzi H. Arvores brasileiras: manual de identificacao e cultivo de plantas arboreas nativas do Brasil. 5th ed: Nova Odessa: Instituto Plantarum de Estudos da Flora; 2008.
124. Alice CB, de Siqueira NCS, Mentz LA, Silva GAAB, Jose KFD. Plantas medicinais de uso popular: atlas farmacognostico. Porto Alegre: Editora da ULBRA; 1995.
125. Klafke JZ, Porto FG, Batista R, et al. Association between hypertriglyceridemia and protein oxidation and proinflammatory markers in normocholesterolemic and hypercholesterolemic individuals. Clin Chim Acta 2015; 448: 50-7.
126. Klafke JZ, Porto FG, de Almeida AS, et al. Biomarkers of Subclinical Atherosclerosis and Natural Products as Complementary Alternative Medicine. Curr Pharm Des 2016; 22(3): 372-82.
127. Klafke JZ, Arnoldi da Silva M, Fortes Rossato M, et al. Antiplatelet, Antithrombotic, and Fibrinolytic Activities of Campomanesia xanthocarpa. Evidence-based complementary and alternative medicine: eCAM 2012; 2012: 954748.
128. Klafke JZ, Pereira RL, Hirsch GE, et al. Study of oxidative and inflammatory parameters in LDLr-KO mice treated with a hypercholesterolemic diet: Comparison between the use of Campomanesia xanthocarpa and acetylsalicylic acid. Phytomedicine 2015; 23(11): 1227-34.
129. Markman BE, Bacchi EM, Kato ET. Antiulcerogenic effects of Campomanesia xanthocarpa. J Ethnopharmacol 2004; 94(1): 55-7.
130. Yoshiki Y, Kudou S, Okubo K. Relationship between chemical structures and biological activities of triterpenoid saponins from soybean. Biosci, Biotechnol, Biochem 1998; 62(12): 2291-9.
131. Manaargadoo-Catin M, Ali-Cherif A, Pougnas JL, Perrin C. Hemolysis by surfactants-A review. Adv Colloid Interface Sci 2016; 228: 1-16.
132. Dinda B, Debnath S, Mohanta BC, Harigaya Y. Naturally occurring triterpenoid saponins. Chem Biodiversity 2010; 7(10): 2327-580.
133. Francis G, Kerem Z, Makkar HP, Becker K. The biological action of saponins in animal systems: a review. Br J Nutr 2002; 88(6): 587-605.
134. Small DM. Surface and bulk interactions of lipids and water with a classification of biologically active lipids based on these interactions. Federation Proc 1970; 29(4): 1320-6.
135. Augustin JM, Kuzina V, Andersen SB, Bak S. Molecular activities, biosynthesis and evolution of triterpenoid saponins. Phytochemistry 2011; 72(6): 435-57.
136. Bottger S, Hofmann K, Melzig MF. Saponins can perturb biologic membranes and reduce the surface tension of aqueous solutions: a correlation? Bioorganic Med Chem 2012; 20(9): 2822-8.
137. Shany S, Bernheimer AW, Grushoff PS, Kim KS. Evidence for membrane cholesterol as the common binding site for cereolysin, streptolysin O and saponin. Mol Cell Biochem 1974; 3(3): 179-86.
138. Elekofehinti OO, Kamdem JP, Kade IJ, Rocha JBT, Adanlawo IG. Hypoglycemic, antiperoxidative and antihyperlipidemic effects of saponins from Solanum anguivi Lam. fruits in alloxan-induced diabetic rats. S Afr J Bot 2013; 88: 56-61.
139. Gulcin I, Kufrevioglu OI, Oktay M, Buyukokuroglu ME. Antioxidant, antimicrobial, antiulcer and analgesic activities of nettle (Urtica dioica L.). J Ethnopharmacol 2004; 90(2-3): 205-15.
140. Malomo SO, Ore A, Yakubu MT. In vitro and in vivo antioxidant activities of the aqueous extract of Celosia argentea leaves. Indian J Pharmacol 2011; 43(3): 278-85.
141. Song YB, An YR, Kim SJ, et al. Lipid metabolic effect of Korean red ginseng extract in mice fed on a high-fat diet. J Sci Food Agric 2012; 92(2): 388-96.
142. Elekofehinti OO. Saponins: Anti-diabetic principles from medicinal plants-A review. Pathophysiology: the official J International Society for Pathophysiology/ISP 2015; 22(2): 95-103.
143. Lee JG, Lee YY, Kim SY, Pyo JS, Yun-Choi HS, Park JH. Platelet antiaggregating activity of ginsenosides isolated from processed ginseng. Die Pharmazie 2009; 64(9): 602-4.
144. Shin BK, Kwon SW, Park JH. Chemical diversity of ginseng saponins from Panax ginseng. J Ginseng Res 2015; 39(4): 287-98.
145. Jeon BR, Kim SJ, Hong SB, Park HJ, Cho JY, Rhee MH. The inhibitory mechanism of crude saponin fraction from Korean Red Ginseng in collagen-induced platelet aggregation. J Ginseng Res 2015; 39(3): 279-85.
146. Hao DCG, Xiao PG, Liang ZG, Xu LJ, Peng Y. Research progress in the phytochemistry and biology of Ilex pharmaceutical resources. Acta Pharm 2013; 3: 8-19.
147. Kothiyal SK, Sati SC, Rawat MSM, et al. Chemical constituents and biological significance of the genus Ilex (Aquifoliaceae). J Nat Prod 2012; 2: 2212-24.
148. Heck CI, de Mejia EG. Yerba mate tea (Ilex paraguariensis): a comprehensive review on chemistry, health implications, and technological considerations. J Food Sci 2007; 72(9): 138-51.
149. Dahmer T, Berger M, Barlette AG, et al. Antithrombotic effect of chikusetsusaponin IVa isolated from Ilex paraguariensis (Mate). J medicinal food 2012; 15(12): 1073-80.
150. Wang B, Liu Y, Shang Q, Zhang Q, Zhang L, Liu J, et al. Interaction of Panax quinquefolius Saponin and Dual Antiplatelets on Vascular Endothelial Function in Rats with Acute Myocardial Infarction. Biomed Res Int 2015; 2015: 932751.
151. Leung KW, Wong AS. Pharmacology of ginsenosides: a literature review. Chinese medicine 2010; 5: 20.
152. Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug metabolism and disposition: the biological fate of chemicals 2003; 31(8): 1065-71.
153. Cook NC, Samman S. Flavonoids-Chemistry, metabolism, cardioprotective effects, and dietary sources. Nutr Biochem 1996; 7(2): 66-76.
154. Coultate TP. Food: The Chemistry of lts Components. 2nd ed. ed: The Royal Society of Chemistry; 1990.
155. Pietta PG. Flavonoids as Antioxidants. J Nat Prod 2000; 63: 1035-42.
156. Dixon RA, Paiva NL. Stress-induced phenylpropanoid metabolism. The Plant cell 1995; 7(7): 1085-97.
157. Cody V. Crystal and molecular structure of flavonoids. In: Liss AL, editor. Plant flavonoids in biology and medicine II: Biochemical, cellular, and medicinal properties. France: Proceeding 1987.
158. Harborne JB. Nature, distribution and function of plant flavonoids. Progress in clinical and biological Res 1986; 213: 15-24.
159. Harborne JB. Flavonoids in the environment: structure-activity relationships. Prog Clin Biol Res 1988; 280: 17-27.
160. Karlickova J, Riha M, Filipsky T, Macakova K, Hrdina R, Mladenka P. Antiplatelet Effects of Flavonoids Mediated by Inhibition of Arachidonic Acid Based Pathway. Planta Med 2016; 82(1-02): 76-83.
161. Lin CN, Lee TH, Hsu MF, Wang JP, Ko FN, Teng CM. 2’,5’-Dihydroxychalcone as a potent chemical mediator and cyclooxygenase inhibitor. J Pharmacy Pharmacol 1997; 49(5): 530-6.
162. Lin CN, Lu CM, Lin HC, et al. Novel antiplatelet constituents from formosan moraceous plants. J Nat Prod 1996; 59(9): 834-8.
163. Lin CNH, Ko HH, Hsu MF, et al. Chalcones as potent antiplatelet agents and calcium channel blockers. Drug Develop Res 2001; 53: 9-14.
164. Wu CM, Lin KW, Teng CH, et al. Chalcone derivatives inhibit human platelet aggregation and inhibit growth in human bladder cancer cells. Biol Pharm Bull 2014; 37(7): 1191-8.
165. Tzeng SHK, Ko WC, Teng FN. Inhibition of platelet aggregation by some flavonoids. Thrombosis Res 1991; 64: 91-100.
166. Hubbard GP, Stevens JM, Cicmil M, et al. Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway. J Thrombosis Haemostasis 2003; 1(5): 1079-88.
167. Guerrero JA, Lozano ML, Castillo J, Benavente-Garcia O, Vicente V, Rivera J. Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J Thrombosis Haemostasis 2005; 3(2): 369-76.
168. Sheu JR, Hsiao G, Chou PH, Shen MY, Chou DS. Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonol quercetin, in human platelets. J Agric Food Chem 2004; 52(14): 4414-8.
169. Wang H, Nair MG, Strasburg GM, Booren AM, Gray I, Dewitt DL. Cyclooxygenase active bioflavonoids from Balaton tart cherry and their structure activity relationships. Phytomedicine: international J Phytother Phytopharmacol 2000; 7(1): 15-9.
170. Bucki R, Pastore JJ, Giraud F, Sulpice JC, Janmey PA. Flavonoid inhibition of platelet procoagulant activity and phosphoinositide synthesis. J Thrombosis Haemostasis 2003; 1(8): 1820-8.
171. Bojic M, Debeljak Z, Tomicic M, Medic-Saric M, Tomic S. Evaluation of antiaggregatory activity of flavonoid aglycone series. Nutr J 2011; 10: 73.
172. Innes AJ, Kennedy G, McLaren M, Bancroft AJ, Belch JJ. Dark chocolate inhibits platelet aggregation in healthy volunteers. Platelets 2003; 14(5): 325-7.
173. Rein D, Paglieroni TG, Wun T, et al. Cocoa inhibits platelet activation and function. Am J Clin Nutr 2000; 72(1): 30-5.
174. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007; 297(18): 2018-24.
175. Pearson DA, Paglieroni TG, Rein D, et al. The effects of flavanolrich cocoa and aspirin on ex vivo platelet function. Thrombosis Res 2002; 106(4-5): 191-7.
176. Eccleston C, Baoru Y, Tahvonen R, Kallio H, Rimbach GH, Minihane AM. Effects of an antioxidant-rich juice (sea buckthorn) on risk factors for coronary heart disease in humans. J Nutr Biochem 2002; 13(6): 346-54.
177. Gooderham MH, Adlercreutz H, Ojala ST, Wahala K, Holub BJ. A soy protein isolate rich in genistein and daidzein and its effects on plasma isoflavone concentrations, platelet aggregation, blood lipids and fatty acid composition of plasma phospholipid in normal men. J Nutr 1996; 126(8): 2000-6.
178. Janssen K, Mensink RP, Cox FJ, et al. Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: results from an in vitro and a dietary supplement study. Am J Clin Nutr 1998; 67(2): 255-62.
179. Borges F, Roleira F, Milhazes N, Santana L, Uriarte E. Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr Med Chem 2005; 12(8): 887-916.
180. Borges FR, Milhazes N, Uriarte E, Santana L. Simple coumarins: Privileged scaffolds in medicinal chemistry. Frontiers Med Chem 2009; 4: 23-85.
181. Wu L, Wang X, Xu W, Farzaneh F, Xu R. The structure and pharmacological functions of coumarins and their derivatives. Curr Med Chem 2009; 16(32): 4236-60.
182. Bourgaud R, Larbat S, Doerper E, Gontier S, Kellner U. Biosynthesis of coumarins in plants: a major pathway still to be unravelled for cytochrome P450 enzymes. Phytochem Rev 2006; 5: 293-308.
183. Isabelle H, Stephane C, Lionel P, et al. 6-substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid derivatives in a new approach of the treatment of cancer cell invasion and metastasis. Eur J Med Chem 2008; 43: 2735-50.
184. Win NN, Awale S, Esumi H, Tezuka Y, Kadota S. Novel anticancer agents, kayeassamins C-I from the flower of Kayea assamica of Myanmar. Bioorganic Med Chem 2008; 16(18): 8653-60.
185. Kumar A, Singh BK, Sharma NK, et al. Specificities of acetoxy derivatives of coumarins, biscoumarins, chromones, flavones, isoflavones and xanthones for acetoxy drug: protein transacetylase. Eur J Med Chem 2007; 42(4): 447-55.
186. Kumar A, Singh BK, Tyagi R, et al. Mechanism of biochemical action of substituted 4-methylcoumarins. Part 11: Comparison of the specificities of acetoxy derivatives of 4-methylcoumarin and 4-phenylcoumarin to acetoxycoumarins: protein transacetylase. Bioorganic Med Chem 2005; 13(13): 4300-5.
187. Kalkhambkar GM, Kamanavalli CM, Premkumar N, Asdag SMB, Sun CM. Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins. Eur J Med Chem 2008; 43: 2178-88.
188. Grimm EL, Brideau C, Chauret N, et al. Substituted coumarins as potent 5-lipoxygenase inhibitors. Bioorganic Med Chem Lett 2006; 16(9): 2528-31.
189. Arora RB, Mathur CN. Relationship between structure and anticoagulant activity of coumarin derivatives. Br J Pharmacol Chemother 1963; 20(1): 29-35.
190. Madari H, Panda D, Wilson L, Jacobs RS. Dicoumarol: a unique microtubule stabilizing natural product that is synergistic with Taxol. Cancer Res 2003; 63(6): 1214-20.
191. Leoncini G, Signorello MG, Bruzzese D, Di Braccio M, Grossi GC, Roma G. Mechanisms involved in the antiplatelet activity of 8-methyl-4(1-piperazinyl)-7-(3-pyridinylmethoxy)-2H-1-benzopyran-2-one (RC414). Biochem Pharmacol 2004; 67(5): 911-8.
192. Chia YC, Chang FR, Wang JC, et al. Antiplatelet aggregation coumarins from the leaves of Murraya omphalocarpa. Molecules 2008; 13(1): 122-8.
193. Chen KS, Wu CC, Chang FR, et al. Bioactive coumarins from the leaves of Murraya omphalocarpa. Planta Med 2003; 69(7): 654-7.
194. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119(1 Suppl): 8S-21S.
195. Frederick R, Robert S, Charlier C, et al. 3,6-Disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa. J Med Chem 2005; 48(24): 7592-603.
196. Leoncini G, Signorello MG, Bruzzese D, Di Braccio M, Grossi GC, Roma G. Mechanisms involved in the antiplatelet activity of 8-methyl-4-(1-piperazinyl)-7-(3-pyridinylmethoxy)-2H-1-benzopyran-2-one (RC414). Biochem Pharmacol 2004; 67(5): 911-8.
197. Di Braccio M, Grossi G, Signorello MG, et al. Synthesis, in vitro antiplatelet activity and molecular modelling studies of 10-substituted 2-(1-piperazinyl)pyrimido [1,2-a]benzimidazol-4(10H)-ones. Eur J Med Chem 2013; 62: 564-78.
198. Macakova K, Rehakova Z, Mladenka P, et al. In vitro platelet antiaggregatory properties of 4-methylcoumarins. Biochimie 2012; 94(12): 2681-6.
199. Tsai IL, Wun MF, Teng CM, Ishikawa T, Chen IS. Anti-platelet aggregation constituents from formosan Toddalia asiatica. Phytochemistry 1998; 48(8): 1377-82.
200. Di Braccio M, Grossi G, Roma G, Signorello MG, Leoncini G. Synthesis and in vitro inhibitory activity on human platelet aggre gation of novel properly substituted 4-(1-piperazinyl)coumarins. Eur J Med Chem 2004; 39(5): 397-409.
201. Sashidhara KV, Palnati GR, Avula SR, Singh S, Jain M, Dikshit M. Synthesis and evaluation of anti-thrombotic activity of benzocoumarin amide derivatives. Bioorganic Med Chem Lett 2012; 22(9): 3115-21.
202. Chen YWT, Lee K, Tzeng C, Chang Y, Teng C. Synthesis of coumarin derivatives as hibitors of platelet aggregation. Helvetica Chimica Acta 1996; 79: 651-7.
203. Mladenka P, Zatloukalova L, Filipsky T, Hrdina R. Cardiovascular effects of flavonoids are not caused only by direct antioxidant activity. Free Radical Bio Med 2010; 49(6): 963-75.
204. de las Heras B, Rodriguez B, Bosca L, Villar AM. Terpenoids: sources, structure elucidation and therapeutic potential in inflammation. Curr Topics Med Chem 2003; 3(2): 171-85.
205. Paduch R, Kandefer-Szerszen M, Trytek M, Fiedurek J. Terpenes: substances useful in human healthcare. Arch Immunol Ther Exp 2007; 55(5): 315-27.
206. Rohmer M. The discovery of a mevalonate-independent pathway for isoprenoid biosynthesis in bacteria, algae and higher plants. Nat Prod Rep 1999; 16(5): 565-74.
207. Gao SS. In vitro percutaneous absorption enhancement of lipophilic drug tamoxifen by terpenes. J Controlled Release 1998; 51: 193-9.
208. Harrewijin PvO AM, Piron, PGM. Natural Terpenoids as messengers: A multidisciplinary study of their production, biological function and practical applications: Kluwer Acadamic Publishers: The Netherlands; 2001.
209. Breitmaier E. Terpenes: Flavors, Fragrances, Pharmaca, Pheromones. Weinheim, Germany: Wiley-VCH; 2006.
210. McGarvey DJ, Croteau R. Terpenoid metabolism. The Plant Cell 1995; 7(7): 1015-26.
211. Ajikumar PK, Tyo K, Carlsen S, Mucha O, Phon TH, Stephanopoulos G. Terpenoids: opportunities for biosynthesis of natural product drugs using engineered microorganisms. Mol Pharm 2008; 5(2): 167-90.
212. Langenheim JH. Higher plant terpenoids: A phytocentric overview of their ecological roles. J Chem Ecol 1994; 20(6): 1223-80.
213. Crowell PL. Monoterpenes in breast cancer chemoprevention. Breast Cancer Res Treatment 1997; 46(2-3): 191-7.
214. de Andrade Moura L, Marqui de Almeida AC, Domingos TF, et al. Antiplatelet and anticoagulant effects of diterpenes isolated from the marine alga, Dictyota menstrualis. Marine Drugs 2014; 12(5): 2471-84.
215. Surin WR, Barthwal MK, Dikshit M. Platelet collagen receptors, signaling and antagonism: emerging approaches for the prevention of intravascular thrombosis. Thrombosis Res 2008; 122(6): 786-803.
216. Tzakos AG, Kontogianni VG, Tsoumani M, et al. Exploration of the antiplatelet activity profile of betulinic acid on human platelets. J Agric Food Chem 2012; 60(28): 6977-83.
217. Ching J, Soh WL, Tan CH, et al. Identification of active compounds from medicinal plant extracts using gas chromatographymass spectrometry and multivariate data analysis. J Separation Sci 2012; 35(1): 53-9.
218. Fleming I, Schulz C, Fichtlscherer B, Kemp BE, Fisslthaler B, Busse R. AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets. Thromb Haemostasis 2003; 90(5): 863-71.
219. Murase T, Misawa K, Haramizu S, Minegishi Y, Hase T. Nootkatone, a characteristic constituent of grapefruit, stimulates energy metabolism and prevents diet-induced obesity by activating AMPK. Am J Physiol-Endoc M 2010; 299(2): E266-E75.
220. Seo EJ, Lee DU, Kwak JH, Lee SM, Kim YS, Jung YS. Antiplatelet effects of Cyperus rotundus and its component (+)-nootkatone. J Ethnopharmacol 2011; 135(1): 48-54.
221. Sowden RJ, Yasmin S, Rees NH, Bell SG, Wong LL. Biotransformation of the sesquiterpene (+)-valencene by cytochrome P450(cam) and P450(BM-3). Org Biomol Chem 2005; 3(1): 57-64.
222. Calixto NO, da Costa e Silva MC, Gayer CR, Coelho MG, Paes MC, Todeschini AR. Antiplatelet activity of geranylgeraniol isolated from Pterodon pubescens fruit oil is mediated by inhibition of cyclooxygenase-1. Planta Med 2007; 73(5): 480-3.
223. Lee JJ, Jin YR, Lim Y, et al. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization. Vascular Pharmacol 2006; 45(3): 148-53.
224. Li YH, Sun XP, Zhang YQ, Wang NS. The antithrombotic effect of borneol related to its anticoagulant property. Am J Chinese Med 2008; 36(4): 719-27.